MariMed Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

MEZZANINE EQUITY (Details Narrative)

MEZZANINE EQUITY (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended	6 Months Ended		12 Months Ended
	Mar. 31, 2021	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2020	Apr. 30, 2022
Debt instrument, face amount		$ 8,800
Stock issued during period, value, new issues
Class of warrant or right, number of securities called by warrants or rights		24,676,571			750,000
Warrant exercise price		$ 0.89
Payments of stock issuance costs			$ 387
Proceeds from issuance or sale of equity	$ 23,000
Payments for construction in process	7,300
Repayments of debt and lease obligation	$ 15,700
Common Stock [Member]
Stock issued during period, shares, new issues			11,413
Hadron Healthcare Master Fund [Member] \| Warrant [Member]
Warrant exercise price	$ 1.087
Fair value adjustment of warrants	$ 9,500
Payments of stock issuance costs	$ 400
Hadron Healthcare Master Fund [Member] \| Maximum [Member] \| Common Stock [Member]
Class of warrant or right, number of securities called by warrants or rights	15,540,540
Securities Purchase Agreement [Member] \| Hadron Healthcare Master Fund [Member] \| Warrant [Member]
Warrants term	4 years
Series B Convertible Preferred Stock [Member]
Shares issued, price per share		$ 3.00
Preferred stock, convertible conversion price		$ 3.00
Preferred stock conversion, description		(ii) the Company has the option to convert all, but not less than all, shares of Series B Stock into common stock at a conversion price of $3.00 if the daily volume weighted average price of common stock (the “VWAP”) exceeds $4.00 per share for at least twenty consecutive trading days prior to the date on which the Company gives notice of such conversion to the Series B Holders.
Series B Convertible Preferred Stock [Member] \| Volume Weighted Average Price Less Than Or Equal To $0.50 Per Share [Member]
Preferred stock conversion, description		If the sixty-day VWAP is less than or equal to $0.50 per share, the Company shall have the option to (i) convert all shares of Series B Stock into common stock at a conversion price of $1.00 per share, and pay cash to the Series B Holders equal to the difference between the sixty-day VWAP and $3.00 per share, or (ii) pay cash to the Series B Holders equal to $3.00 per share.
Series B Convertible Preferred Stock [Member] \| Volume Weighted Average Price Greater Than $0.50 Per Share [Member]
Preferred stock conversion, description		If the sixty-day VWAP is greater than $0.50 per share, the Company shall have the option to (i) convert all shares of Series B Stock into common stock at a conversion price per share equal to the quotient of $3.00 per share divided by the sixty-day VWAP, or (ii) pay cash to the Series B Holders equal to $3.00 per share, or (iii) convert all shares of Series B Stock into common stock at a conversion price per share equal to the sixty-day VWAP and pay cash to the Series B Holders equal to the difference between $3.00 per share and the sixty-day VWAP.
Series B Convertible Preferred Stock [Member] \| Exchange Agreement [Member] \| Two Unaffiliated Institutional Shareholders [Member]
Debt instrument, face amount				$ 4,400
Conversion of stock, shares converted				4,908,333
Series C Convertible Preferred Stock [Member] \| Hadron Healthcare Master Fund [Member] \| Warrant [Member]
Stock issued during period, shares, new issues	6,216,216
Series C Convertible Preferred Stock [Member] \| Securities Purchase Agreement [Member] \| Hadron Healthcare Master Fund [Member]
Shares issued, price per share	$ 3.70
Stock issued during period, value, new issues	$ 23,000
Series C Convertible Preferred Stock [Member] \| Securities Purchase Agreement [Member] \| Hadron Healthcare Master Fund [Member] \| Maximum [Member]
Stock issued during period, shares, new issues	46,000,000.0